The Researcher OG

The Researcher OG Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from The Researcher OG, Alternative & holistic health service, Santa Barbara, CA.
(4)

Mike Robinson, Researcher OG
Ask for a Free ECS Consult

Creator of Researcher®️ Genevieve's Dream™️ Nano Terps®️ Thermonoids®️ GENEVEX®️ Plant Chat®️ PREVENT®️ Get Balanced®️ NANO®️ Jane®️ & more

CEO Nanobles/Global Cannabinoid Research Center GCRC

Make the best out of your day, celebrate and have a blast. The plant is free, forever, it's been declared medicine and i...
04/20/2026

Make the best out of your day, celebrate and have a blast. The plant is free, forever, it's been declared medicine and is the object of attention of so many that have never touched it, and will never touch it, trying to duplicate it's powers - which will never happen!

Kidney disease isn’t just filtration failure. It’s inflammation, oxidative stress, fibrosis, vascular pressure, tubular ...
04/20/2026

Kidney disease isn’t just filtration failure. It’s inflammation, oxidative stress, fibrosis, vascular pressure, tubular injury, metabolic strain, and damaged signaling wearing down the organ that cleans the blood every minute of the day.

In “Cannabinoid Receptor 1 Inhibition in Chronic Kidney Disease: A New Therapeutic Toolbox” (2021), researchers reviewed how the ECS, our Master Regulator, may influence chronic kidney disease through CB1 and CB2 receptor activity. What hits hard is that CB1 activation in the kidney is linked to oxidative stress, inflammation, fibrosis, glomerular injury, and tubular damage, while CB2 activity appears to act in a more protective manner.

That matters because CKD often builds slowly, then suddenly becomes life-changing. The kidney’s tiny filtering units depend on podocytes, tubules, blood vessels, and immune balance staying coordinated. When CB1 signaling becomes overactive in response to metabolic stress, diabetes, obesity, or renal injury, the system can shift toward scarring rather than repair.

The researchers describe CB1 inhibition as a potential therapeutic target, especially when designed to act outside the brain to avoid central side effects. That’s a big distinction. We’re not talking about getting someone high. We’re talking about cannabinoid-system pharmacology aimed at kidney tissue, inflammation control, lipid metabolism, albuminuria, and fibrosis pathways.

This is where cannabinoid science grows up. Kidney disease needs precision, not hype. The ECS is already woven into renal function, and when that system is pushed out of balance, the damage can become structural. Targeting the right cannabinoid pathway may help shift the kidney conversation from decline management toward biological protection.

-Mike Robinson, The Researcher OG

Study: https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2021.720734/full

I picked “Acute Cannabigerol Administration Lowers Blood Pressure in Mice” (2022) because it’s recent, CBG-specific, and...
04/20/2026

I picked “Acute Cannabigerol Administration Lowers Blood Pressure in Mice” (2022) because it’s recent, CBG-specific, and directly tied to cardiovascular regulation through blood pressure, vascular tone, sympathetic signaling, and α2-adrenoreceptor activity.

Cardiovascular disease isn’t just a clogged pipe problem. It’s pressure, tone, inflammation, stress chemistry, vessel response, and signaling control all pushing the heart and vascular system toward imbalance.

In “Acute Cannabigerol Administration Lowers Blood Pressure in Mice” (2022), researchers tested CBG in conscious male mice using radiotelemetry to track blood pressure, heart rate, and movement. The result matters because CBG significantly lowered mean, systolic, and diastolic blood pressure, without altering locomotor activity or the sedative drag that can complicate cannabinoid research.

The mechanism is where this gets interesting. The study points to α2-adrenergic receptor activity, a pathway linked to norepinephrine release and sympathetic nervous system output. In plain language, CBG may help quiet some of the pressure-driving signals that tell blood vessels and cardiovascular organs to tighten up and stay on alert.

That doesn’t mean consumers should treat CBG like a casual blood pressure tool. The researchers also raised caution, especially for healthy individuals, because excessive pressure reduction can become an issue in its own right. But for cardiovascular disease research, especially hypertension-related work, this gives CBG a serious seat at the table.

CBG isn’t just another minor cannabinoid anymore. It’s showing up in the cardiovascular conversation through real mechanisms, and when the ECS, our Master Regulator, connects with blood pressure regulation, vascular tone, and stress signaling, the old “weed science” stereotype gets left in the dust where it belongs.

-Mike Robinson, The Researcher OG

Study: https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2022.871962/full

Medical cannabis laws didn’t just change access; they opened a harm-reduction door in the middle of an opioid disaster. ...
04/19/2026

Medical cannabis laws didn’t just change access; they opened a harm-reduction door in the middle of an opioid disaster. The 2025 study, "Cannabis Laws and Opioid Use Among Commercially Insured Adults With Cancer Receiving Systemic Therapy" (2025), found that medical cannabis dispensary openings were associated with significant reductions in multiple opioid outcomes, including fewer opioid fills, lower daily morphine milligram equivalents, and fewer days supplied.

That matters because pain patients do not live on theory; they live on what lowers their daily burden. In that study, the drop was not small talk either. After medical dispensary openings, patients with cancer had lower rates of any opioid use, lower long-acting opioid use, lower high-dose opioid use, and fewer opioid prescriptions overall, which supports the idea that legal cannabis access can function as a substitution and harm reduction in real clinical life.

Now here’s where the conversation has to stay honest. Recent population-level research has not shown a clean, universal drop in overall opioid overdose deaths after medical or recreational cannabis laws, although one 2024 JAMA Health Forum study did find a possible reduction in synthetic opioid deaths after recreational cannabis laws. That means the strongest modern evidence is clearer on reduced opioid use than on guaranteed reductions in all opioid mortality.

So the sharper takeaway is this - legal cannabis has shown real harm-reduction potential by lowering opioid use in important groups, and that alone matters. Fewer fills, fewer high-dose exposures, and less reliance on opioids is a meaningful public health win, even while the overdose death question stays more mixed in recent large studies.

-Mike Robinson Researcher OG

Study: https://jamanetwork.com/journals/jama-health-forum/fullarticle/2840030

Endocannabinoids are not just background chemistry - they help the brain decide what gets stored, what gets recalled, an...
04/19/2026

Endocannabinoids are not just background chemistry - they help the brain decide what gets stored, what gets recalled, and how well we navigate the world around us. The 2023 review, "Endocannabinoid regulation of hippocampus-dependent memory" (2023), explains that the endocannabinoid system regulates episodic and hippocampal-dependent memory, with direct relevance to learning, recall, and the hippocampal processes tied to spatial memory.

That matters because spatial memory is not some side function. It is part of how we orient, adapt, and build cognitive resilience over time. This review delves into the machinery, showing that endocannabinoid signaling influences memory encoding, consolidation, retrieval, extinction, synaptic plasticity, and intracellular signaling in the hippocampus, one of the brain’s core memory centers.

What makes this important for cognitive health is balance. The authors note that CB1 receptors are highly expressed in the hippocampus, and they frame the ECS as a regulator of the very processes that shape hippocampal-dependent memory.

That means endocannabinoids like anandamide and 2-AG are part of the brain’s own memory-tuning system, helping manage signaling in a way that affects how experiences are laid down and later accessed.

The caution is that more is not always better. The same review says the bulk of available evidence suggests cannabinoids can be detrimental to memory from encoding to retrieval when CB1 signaling is pushed too hard, while the broader lesson is that endogenous signaling is part of normal memory regulation.

That’s exactly why endocannabinoid tone matters - not just for feeling balanced, but for protecting the timing, flexibility, and health of cognition itself.

-Mike Robinson Researcher OG

Study: https://doi.org/10.1016/j.expneurol.2023.114384

Getting older can be brutal, you can be bummed about it, or you can take it by the horns! I will be 44 yrs young on Sund...
04/18/2026

Getting older can be brutal, you can be bummed about it, or you can take it by the horns! I will be 44 yrs young on Sunday and with my extra gray hairs I choose to embrace it!

The only thing that bums me out about it is the fact that it is a day shy of 4/20! Lol

But I have my family, my health(🤞seizures stay away), my weight going lower, and my love for plants, inside and outside.

It's going to be a good birthday weekend and I hope everyone else enjoys it as much as I do!

Pain patients often don’t just need stronger signal blocking; they need better internal regulation so the whole pain sys...
04/17/2026

Pain patients often don’t just need stronger signal blocking; they need better internal regulation so the whole pain system stops running hot. The 2024 review, "The endocannabinoid system as a therapeutic target in neuropathic pain: a review" (2024), laid out the ECS as a real regulator of neuropathic pain across peripheral, spinal, and supraspinal pathways, which is why cannabinoids may help by modulating the system that processes pain instead of only trying to shut the signal down.

That difference matters. Opioids mainly reduce excitatory neurotransmitter release through mu, kappa, and delta opioid receptor activity, and they change pain perception in the brain while raising pain threshold in the spinal cord.

Cannabinoids also decrease neurotransmitter release, but they additionally activate descending inhibitory pain pathways, reduce postsynaptic sensitivity, and help regulate neural inflammation, which makes them more about reading, modulating, and recalibrating pain traffic than simply putting a blanket over it.

That’s why ECS balance matters so much in chronic pain. The 2024 review notes that the ECS is expressed throughout the ascending and descending pain pathways, that CB2 signaling is especially relevant in inflammatory and neuropathic states, and that local endocannabinoid levels and cannabinoid receptor expression can increase in response to injury or disease as part of a protective analgesic response.

In plain language, the body is already trying to regulate pain from the inside, and cannabinoids may work better when they support that balancing network instead of replacing it with one blunt force strategy.

So the sharper way to say it is this - opioids can block pain signals, but cannabinoids help interpret, regulate, and cool the environment those signals are moving through. That’s a different kind of pain medicine, and for many patients it may be the difference between temporary suppression and better internal balance.

-Mike Robinson Researcher OG

Study: https://www.tandfonline.com/doi/abs/10.1080/14728222.2024.2407824

Mood support is where this conversation has to stay honest, because feeling better in the moment is not the same thing a...
04/16/2026

Mood support is where this conversation has to stay honest, because feeling better in the moment is not the same thing as proving cannabis treats depression as a disease. The 2025 study, "Measuring the Effects of Cannabis on Anxiety and Depression Among Cancer Patients" (2025), found that self-reported depression symptoms improved more in cancer patients using enteral cannabis products, while anxiety improved more when patterns of use included relatively higher CBD doses.

That matters because mood isn't a simple on-or-off switch. In this longitudinal analysis of 1,962 patients in the Minnesota Medical Cannabis Program, the authors looked at how dose, THC:CBD ratio, and route of use related to symptom changes after 30 days.

Their conclusion was careful, but important - patterns of cannabis use that included relatively higher CBD taken enterally may improve quality of life for cancer survivors reporting anxiety and depression. That puts cannabis in the mood support lane, not the miracle cure lane.

The bigger lesson is balance. This paper suggests mood outcomes were not uniform across all cannabis use, which means the product profile and delivery route matter. Higher CBD patterns looked more favorable for anxiety, while depression improvements tracked more with enteral use than with a simple THC-heavy approach.

That fits the broader idea that cannabinoids may support mood better when used with some balance and intention, instead of chasing intoxication alone.

So the clean takeaway is this - cannabis may offer mood support in some settings, especially when CBD is part of the picture, but that is different from saying cannabis has proven efficacy as a standalone treatment for depression.

For symptom burden, stress load, and quality of life, though, this study gives the support conversation some real ground to stand on.

-Mike Robinson Researcher OG

Study: https://www.ncbi.nlm.nih.gov/pubmed/41163433

Address

Santa Barbara, CA

Opening Hours

Monday 10am - 6pm
Tuesday 7am - 5pm
Wednesday 7am - 5pm
Thursday 2pm - 10pm
Friday 2pm - 10pm
Saturday 10am - 5pm
Sunday 6pm - 10pm

Website

https://GlobalCannabinoidRC.com/, https://GenevievesDream.com/

Alerts

Be the first to know and let us send you an email when The Researcher OG posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Featured

Share

Category